Cuba is looking forward to an increase in tourist flow from Qatar as the Caribbean country is preparing to host an International Tourism Fair (FITCuba 2017) about 40 days from now. The fair would be held between May 3 and 6. At a presentation on tourism prospects in his country, Cuban ambassador Eumelio Caballero Rodriguez said the fair, the most important professional event of Cuba’s tourism industry, will be held in Holguin, which he described as one of the most exotic tourism destinations of the entire South American continent.
HAVANA. — The United Nations expressed its full support for Cuba this March 22, in order to contribute to the sustainable management of water resources in the country in the face of challenges such as drought and food security. UN Resident Coordinator in Cuba, Myrta Kaulard, noted that this multilateral body and its agencies are entirely disposed to supporting the Caribbean nation.
Havana.– Representatives of non-governmental organizations from Latin America and the Caribbean praised Cuba’s policies to promote the social wellbeing of disabled persons. Speaking exclusively with ACN, Sandra Darce Mendoza, a member of the Admissions Committee for the Latin American Network of Non-Governmental Organizations of Persons with Disabilities and their Families (Riadis), commented on the island’s inclusive programs and training centers for this section of the population.
This week Cuba will once again become the capital of the Caribbean, as it hosts various events addressing key issues for the region, such as tourism, trade, combating climate change and transport.
Events will kick-off in Havana on March 8 with the Association of Caribbean States’ (ACS-AEC) First Cooperation Conference, which will see the participation of representatives from international organizations and countries which, given their experience in the field, could contribute to the region’s development.
February 28, 2017. Written by The Daily Observer. Published in Cuba
A therapeutic vaccine aimed at reducing the viral load of patients with Human Immunodeficiency Virus (HIV), is currently in phase one of a clinical trial, in which its safety is studied.